Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Buy Back $750M in Stock

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that its board of directors has approved the repurchase of $750 million of the firm's common stock on the open market or through negotiated transactions.

The firm said that the purchase authorization will remain in effect through Nov. 9, 2012. As of today, it has $25 million remaining under an existing share repurchase program.

Thermo Fisher officials said a few weeks ago on the firm's third-quarter conference call that the company had deployed $225 million to buy back 4 million shares of its stock during the quarter. In the first nine months of 2011, the company repurchased a total of 17.4 million shares for about $1 billion.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.